SCHEMBL260169

SCHEMBL260169

COC1OC(COCc2ccccc2)C(OCc2ccccc2)C1O

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SSTR1 P30872 1/20 0.57
SSTR2 P30874 1/20 0.57
SSTR4 P31391 1/20 0.57
SSTR3 P32745 1/20 0.57
SSTR5 P35346 1/20 0.57
GJB2 P29033 4/20 0.53
TACR2 P21452 1/20 0.50
LGALS8 O00214 1/20 0.50
NT5E P21589 1/20 0.49
PTPN1 P18031 3/20 0.47
PTPN2 P17706 1/20 0.47
CDC25B P30305 2/20 0.46
SLC6A2 P23975 2/20 0.46
GJA1 P17302 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13598718 1.00 SSTR1 (0.57) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL18880005 1.00 SSTR1 (0.57) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL11066790 1.00 SSTR1 (0.57) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL17039948 1.00 SSTR1 (0.57) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL18671860 1.00 SSTR1 (0.57) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL5981855 1.00 SSTR1 (0.57) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL24371601 1.00 SSTR1 (0.57) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL12896366 1.00 SSTR1 (0.57) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL1262725 1.00 SSTR1 (0.57) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL264401 1.00 SSTR1 (0.57) SSTR1SSTR2SSTR4SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120213735-A1 THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES BIOCRYST PHARMACEUTICALS, INC. (US) 2012-08-23 US disclosed
US-8133870-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2012-03-13 US disclosed
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-12-04 US disclosed
US-7429571-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-09-30 US disclosed
EP-1814561-A2 THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES Biocryst Pharmaceuticals, Inc. (US) 2007-08-08 EP disclosed
US-20060165655-A1 Therapeutic furopyrimidines and thienopyrimidines WILMINGTON TRUST, NATIONAL ASSOCIATION 2006-07-27 US disclosed
WO-2006050161-A2 THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES BIOCRYST PHARMACEUTICALS, INC. (US) 2006-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines DPYD, TYMP, TYMS SSTR1 4452/4885SSTR2 4263/4885SSTR4 4099/4885
US-20060165655-A1 Therapeutic furopyrimidines and thienopyrimidines DPYD, TYMP, TYMS SSTR1 4452/4885SSTR2 4263/4885SSTR4 4099/4885
US-20120213735-A1 THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES DPYD, TYMP, TYMS SSTR1 4452/4885SSTR2 4263/4885SSTR4 4099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.